Geographical and Gender Diversity in Cochrane and non Cochrane Reviews Authorship: A Meta-Research Study

- 3
- 4 Ahmad Sofi-Mahmudi^{*1-3}, ORCiD: 0000-0001-6829-0823
- 5 Jana Stojanova^{4,5}, ORCiD: 0000-0003-4812-5745
- 6 Elpida Vounzoulaki⁶, ORCiD: 0000-0003-3137-8295
- 7 Eve Tomlinson⁷, ORCiD: 0000-0002-0969-602X
- 8 Ana Beatriz-Pizarro⁸, ORCiD: 0000-0003-4089-454X
- 9 Sahar Khademioore², ORCiD: 0000-0002-3025-0006
- 10 Etienne Ngeh⁹, ORCiD: 0000-0002-6555-4085
- 11 Amin Sharifan^{10,11}, ORCiD: 0000-0003-0571-5964
- 12 Lucy Elauteri Mrema¹², ORCiD: 0000-0003-4465-5618
- 13 Alexis Ceecee Britten-Jones¹³⁻¹⁵, ORCiD: 0000-0002-1101-2870
- 14 Santiago Castiello-de Obeso¹⁶, ORCiD: 0000-0002-3672-1366
- 15 Vivian A. Welch^{17,18}, ORCiD: 0000-0002-5238-7097
- 16 Lawrence Mbuagbaw^{1,2,19-21}, ORCiD: 0000-0001-5855-5461
- 17 Peter Tugwell^{17,18,22}, ORCiD: 0000-0001-5062-0556
- 18
- 19 1 National Pain Centre, Department of Anesthesia, McMaster University, Hamilton, ON, Canada.
- 20 2 Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
- 21 **3** Seqiz Health Network, Kurdistan University of Medical Sciences, Seqiz, Kurdistan.
- 4 Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Sydney, NSW, 2010, Australia.
- 23 **5** School of Medicine, Universidad de Valparaiso, Chile.
- 24 6 Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, UK.
- 25 7 Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
- 26 8 Clinical Research Center, Fundación Valle del Lili, Cali, Colombia.
- 27 9 Department of Allied Health Professions, Sheffield Hallam University, L108, 36 Collegiate Crescent, Sheffield S10 2BP, UK.
- 28 10 Department of Pharmaceutical Care, Sina Hospital, Tehran University of Medical Sciences, Iran.
- 29 **11** Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Iran.

- 30 **12** National Institute for Medical Research Mbeya Medical Research Centre, Mbeya, Tanzania.
- 31 13 Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, Australia.
- 32 14 Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
- 33 15 Department of Optometry and Vision Sciences, University of Melbourne, Melbourne, Australia
- 34 **16** Yale University, New Haven, CT 06520, USA.
- 35 17 Bruyere Research Institute, University of Ottawa, Ottawa, ON, Canada.
- 36 **18** School of Epidemiology, University of Ottawa, Ottawa, ON, Canada.
- 37 **19** Biostatistics Unit, Father Sean O'Sullivan Research Centre, Hamilton, ON, Canada.
- 38 20 Centre for Development of Best Practices in Health, Yaoundé Central Hospital, Yaoundé, Cameroon.
- 39 21 Department of Global Health, Stellenbosch University, Cape Town, South Africa.
- 40 22 Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
- 41

42

43 Corresponding author: Ahmad Sofi-Mahmudi; Address: MDCL 2109, McMaster University,
44 1280 Main Street West, Hamilton, ON L8S 4K1, Canada; Telephone: +1 (905) 525-9140 ext.
45 22743; Email: sofima@mcmaster.ca, a.sofimahmudi@gmail.com.

46

47 Conflict of interest disclosure: AS-M, EV, AB-P, EN, AS, LEM, and SC-dO are members of
48 the steering group of the Early Career Professionals Network in Cochrane. ET, VAW, LM, and
49 PT are members of the Health Equity Thematic Group in Cochrane. AB-P and PT are members
50 of the Editorial Board of Cochrane. VAW declares funding from CIHR-PHAC Applied Public
51 Health Chair.

52

53 **Funding disclosure:** This study did not receive any funding.

55 Abstract

56 **Background:** Cochrane is a recognized source of quality evidence that informs health-related 57 decisions. As an organization, it represents a global network of diverse stakeholders. Cochrane's 58 key organizational values include diversity and inclusion, to enable wide participation and 59 promote access. However, the diversity of Cochrane review authorship has not been well 50 summarized.

Objective: The aim of this study was to examine the distribution of country, region, language,
and gender diversity in the authorship of Cochrane and non-Cochrane systematic reviews.

63 **Methods:** We retrieved all published articles from the Cochrane Library (until November 6, 64 2023)—a web crawling technique that extracted pre-specified data fields, including publication 65 date, review type, and author affiliations. We used E-utility calls to capture the data for non-66 Cochrane systematic reviews. We determined the country and region of affiliations and the 67 gender of the first, corresponding, and last authors for Cochrane reviews, as well as the country and region of affiliations and the gender of the first authors for non-Cochrane reviews. Trends in 68 69 geographical and gender diversity over time were evaluated using logistic regression. Fisher's 70 exact test was used for comparisons. The diversity of first authors between Cochrane and non-71 Cochrane reviews was explored through visual presentation, Pearson's product-moment 72 correlation, and the Granger Causality Test. We used R for data collection and analysis.

73 **Results:** A total of 22681 citations were retrieved. The United Kingdom had the highest first-74 author representation (33.2%), followed by Australia (11.6%) and the United States (7.0%). We 75 observed an increase in the proportion of first authors from non-English speaking countries, from 76 16.7% in 1996 to 42.8% in 2023. Female first authorship increased steadily, from 15.0% in 1996 77 to 55.6% in 2023. The proportion of first authors from lower-and-middle-income countries 78 (LMICs) was highest in 2012 at 23.2%. Since then, it has decreased to 18.4% in 2023. Similarly, 79 the proportion of last authors from LMICs decreased over time (25.0% in 1996 vs. 16.2% in 80 2023). Among review groups, Sexually Transmitted Infections and Consumers and 81 Communication were the most and least diverse groups with 68.1% and 1.6% of first authors 82 from LMICs, respectively. In terms of gender diversity, Fertility Regulation had the highest 83 percentage of female first authors (72.1%). Urology (28.1%) had the lowest percentage of female 84 first authors. In 2023, over half of the non-Cochrane reviews had first authors from non-English-

speaking countries (n=14,589, 56.9%), 50.8% (n=13,014) had first authors from LMICs, and
42.3% (n=10,841) had female first authors. The Pearson's product-moment correlations between
Cochrane and non-Cochrane reviews' trends were 0.265 (P=0.450) for LMICs, 0.823 (P<0.001)
for non-English speaking, 0.634 (P<0.001) Spanish-speaking, and 0.829 (P<0.001) for female
first authorship.

90 **Conclusion:** Overall, this study found positive trends, with an increase in first authorship by 91 individuals who were female and from non-English speaking countries. However, the 92 representation of first authors from LMICs decreased. Future research could further explore 93 these trends, identifying potential barriers influencing access and participation of individuals and 94 groups and assessing strategies that help promote diversity and inclusion.

95 *Keywords:* Review; Diversity; Equity; Inclusion; Publications; Authorship; Cochrane

97 Introduction

Global health challenges transcend geographical boundaries. For over 30 years, Cochrane has brought together diverse researchers and stakeholders within a large global network, with the aim of producing high-quality systematic reviews that address important challenges in healthcare (1). These comprehensive reviews are pivotal in guiding clinical practice, policy development, and research agendas (2). A further organizational aim is the translation of research findings, and Cochrane supports global reach in research translation through a network of Geographic Groups, currently representing 54 countries (3).

105 With origins in the United Kingdom, and early membership predominantly representing 106 anglophone countries, Cochrane has grown substantially as an organization with wide global 107 reach. Of the 137 Cochrane Geographic Groups, 114 are from countries where English is not the 108 primary spoken language (3). Cochrane's vision is "a world of better health for all people where 109 decisions about health and care are informed by high quality evidence" with the aim to make 110 evidence accessible to all (1). Collaboration is one of the core values in the organizational 111 strategy (4) and the organization has multiple avenues for participation and inclusion, including 112 membership (predominantly reflecting status as a recent author) and supporter (which may 113 involve active participation through initiatives such as crowd-sourced screening, among many 114 other initiatives) (5). Membership in leadership structures, such as the Governing Board and 115 Council, is attained through member vote, and these entities are structured to support wide 116 representation. Despite this, collated feedback from over 1300 people over the world in a 117 "diversity and inclusion listening and learning exercise," reported by Cochrane in 2022, 118 highlighted that Cochrane is not as diverse and inclusive as it could be, and has work to do to 119 address systemic institutional biases in its systems, processes, and attitudes (6).

Cochrane's key output is the systematic review. Agendas regarding strategic topics for reviews are set by Cochrane Review Groups (CRGs), a majority of which are based in high-income, anglophone countries (6). While some CRGs undertake priority-setting processes involving stakeholders to determine research priorities (7), in line with the 2019 Cochrane Priority Setting Guidance (7), it is unclear how common this is, and Cochrane leadership has recognized that this

125 process often does not have a global focus (8). Furthermore, research has found that Cochrane 126 Reviews tend to be authored primarily by individuals from high-income countries, with limited 127 representation from low- and middle-income countries (9-12). There is also a gender imbalance, 128 with women underrepresented among Cochrane Review authors (13,14). This is an issue, as 129 broad representation of authors from different countries, regions, languages, and genders brings a 130 wider range of experiences, knowledge, and perspectives to the review process, enriching the 131 synthesis and interpretation of evidence (15). This diversity is likely to help to ensure that 132 Cochrane Reviews consider issues of health equity and in turn that the findings apply to a wide 133 range of populations and healthcare settings, or that they specifically address the unique needs 134 and circumstances of disadvantaged groups (16).

135 Publications on this topic today have focused on narrow topics such as hematology (9), eves and 136 vision (10), gastroenterology (11), cardiology (13), and general surgery (14), or a specific 137 geographical location (e.g., sub-Saharan Africa (17)). Thus, this meta-research study aims to 138 assess the distribution of country, region, language, and gender diversity in Cochrane and non-139 Cochrane reviews' authorship. We compared income status (high vs lower-and-middle-income 140 countries (LMICs)), English-speaking countries (vs others), and the gender of the first, last, and 141 corresponding authors. Given that approximately a third of Cochrane Geographic groups are 142 based in Spanish-speaking countries, and have a dedicated conglomerate, Cochrane 143 Iberoamerica, we also evaluated representation from these countries. Further, we investigated 144 diversity in the first authors of non-Cochrane reviews and compared results with those from 145 Cochrane reviews. A fully automated and reproducible approach was applied to systematically 146 extract and analyze author information from both sets of reviews (Cochrane and non-Cochrane).

147

148 Methods

The study protocol was published on the Open Science Framework (OSF) website (<u>https://osf.io/bxj2e</u>). Deviations from the protocol are detailed in Appendix 1. All datasets and codes of workflows used in this study are publically available (OSF: <u>https://osf.io/fv5ys</u>, GitHub:

<u>https://github.com/choxos/cochraneauthors</u>). To ensure transparency and facilitate the
 reproducibility of our analyses, a PDF document containing the codes and corresponding outputs
 is provided in Appendix 2.

155 Data sources and retrieval

All reviews published by Cochrane on the Cochrane Library website (cochranelibrary.com) wereretrieved (up to November 6, 2023).

Since the Cochrane Library provides only the latest version of reviews in their search interface, links to all review versions were automatically created using standard patterns for the digital object identifier (DOI). A typical DOI has the format: "10.1002/14651858.CD" + Review ID + ".pubN".

162 The first version is usually the protocol, and does not include ".pubN". The N represents 163 subsequent protocol versions, e.g. ".pub2" for version 2. All the possible DOIs were created 164 automatically and used for the final extract of Review titles.

We applied a web crawling technique to extract pre-specified data fields for each review from their dedicated information page on the Cochrane Library website (including date, review type, review stage, review group, author position, and author affiliation for all authors). The URL of the review information page was structured as follows:

169 "https://www.cochranelibrary.com/cdsr/doi/" + DOI + "/information"

Authorship position/role was determined (first, last, corresponding). Affiliations were categorized according to country and World Bank economic status. We then categorized the country of the first, corresponding, and last authors in three different ways: (A) high-income vs. LMICs, (B) high-income English-speaking vs. non-English-speaking, and (C) Spanish-speaking vs. non-Spanish-speaking. The list of the countries in each of these categories is available in Appendix 3.

The authors' gender was attributed using the World Gender Name Dictionary 2.0 (18). This database includes approximately 3.5 million names from different languages across the world, and the probability that a name is considered male or female is higher. For this study, we

179 considered the higher probability as the definitive gender and assigned a dichotomous gender180 variable for all authors.

181 Review updates can have the same author composition as the previous version, although there 182 are deviations (for example, see (19–23) and their previous versions). Also, in this study, the unit 183 of analysis is a published paper and not a project. Therefore, we included all the updates of a 184 review in our analyses.

All non-Cochrane systematic reviews were retrieved from PubMed using the following search query: ("Systematic Review" [PT]) NOT ("The Cochrane database of systematic reviews" [Journal], using E-utility calls (24) from 1996 to 2023 (to be comparable with Cochrane reviews). We extracted the PMID, publication date, name, and affiliation of the first author for each review and applied the approach detailed above to ascertain the gender, country, and region.

191 Analysis

192 We used R (25) for data extraction, data processing, analysis, and reporting. Searching and data 193 gathering for non-Cochrane review was done using a bash script available in Appendix 2. Web 194 scraping was done using the *rvest* package (26). Trends over time were reported using 195 descriptive tabulations and graphical illustrations using the ggplot2 package (27). 196 We used logistic regression to explore whether geographical and gender diversity has changed 197 over the years. We also used a random intercept generalized linear model to investigate the trend 198 of geographical and gender diversity among different review groups. To compare the 199 geographical and gender differences between the first, corresponding, and last author between 200 review groups, we performed Fisher's exact test with 2000 replicates.

To compare the trend of first authorship diversity between Cochrane and non-Cochrane reviews, alongside visual presentation and Pearson's product-moment correlation, we also used the Granger Causality Test (28,29). This test assesses whether past values of one time series can predict future values of another. The null hypothesis is that one time series does not cause the other.

206 Validation

To validate the accuracy of the automatically extracted data, we randomly sampled 5% of the dataset and manually verified the names and countries of the first, corresponding, and last authors. This sample is available in Appendix 4.

210

211 **Results**

212 **Overall perspective**

We extracted 22,681 articles, of which 9,153 (40.4%) were the most recent review version and 7,157 (31.6%) were protocols. The annual number of published articles (from 1995 to November 2023) is presented in Appendix 2 (mean=782.1, standard deviation=446.02). Publications peaked in 2012 (n=1,508) and the most recent total was 376 (in 2023). Most articles represented interventional reviews (n=21,965, 96.8%). Diagnostic reviews (n=358, 1.6%) and overviews (n=140, 0.6%) had minor representation.

The Cochrane Review Groups with the highest number of published reviews were Pregnancy and Childbirth (now closed) (n=1,634, 7.2%), Neonatal (n=1,118, 4.9%), and Airways (n=873, 3.8%). Lower representation was apparent for Sexually Transmitted Infections (n=47, 0.2%), Methodology (n=104, 0.5%), and Work (n=108, 0.5%) Groups. Twenty-three reviews were collaborations between two review groups. The yearly trend of the number of reviews by each group is available in Appendix 5.

225 Geographical diversity

Similar trends were observed across different author types (Table 1). First authors were from a greater number of countries compared to the last authors (102 vs. 93). Across author types, 107 countries were represented. Regardless of the author type, most authors were from high-income and English-speaking countries (approximately 80% and 60%, respectively). Most authors were from the United Kingdom, Australia, and the United States (approximately one-third, 10%, and 7% respectively). A World heat map of the countries based on the number of authors is presented

in Figure 1. The detailed information about the countries is available in Appendix 6.

233

| | First authors | Corresponding authors | Last authors |
|--|----------------|--------------------------|----------------|
| Number of countries | 102 | 98 | 94 |
| Number of affiliations where a country could not be identified | 318 (1.4%) | 112 (0.5%) | 442 (1.9%) |
| Number of countries represented by a sole review | 12 (11.8%) | 12 (12.2%) | 8 (8.5%) |
| Most represented countries | | | |
| United Kingdom | 7,426 (33.2%) | 7,412 (33.2%) | 7,720 (34.7%) |
| Australia | 2,595 (11.6%) | 2,619 (11.7%) | 2,640 (11.9%) |
| United States | 1,559 (7.0%) | 1,537 (6.9%) | 1,626 (7.3%) |
| Income status | | | |
| High-income | 18,195 (81.9%) | 18,234 (80.4%) | 18,682 (82.4%) |
| Lower-and-middle-income | 4,016 (18.1%) | 4,446 (19.06%) | 3,998 (17.6%) |
| English speaking country | | | |
| Yes | 13,866 (62.0%) | 13,871 (62.1%) | 14,252 (64.1%) |
| No | 8,497 (38.0%) | 8,469 (37.9%) | 7,987 (35.9%) |
| Spanish speaking country | | | |
| Yes | 753 (3.4%) | 743 (3.3%) | 651 (2.9%) |
| No | 21,610 (96.6%) | 21,597 (96.7%) | 21,588 (97.1) |
| Gender (by first name) | | | |
| Female | 10,545 (50.8%) | 9,947 (48.1%) | 7,804 (37.3%) |
| Male | 10,207 (49.2) | 10,720 (51.9%) | 13,106 (62.7%) |

Table 1. Summary of the number of Cochrane authors by each diversity index (from 22,681 reviews).

235 Please note that the total number for each diversity index is different due to different number of missing values.



237

238 Figure 1. World heat map of the countries based on the number of (A) first, (B) corresponding,

and (C) last authors (in log10 scale).

240

241 Author representation by income status (high/LMIC) and language (English/non-English 242 speaking and Spanish/non-Spanish speaking) over time and by author type are presented in 243 Figure 2. In a given year, LMIC representation was at most 26.7% (first authors in 1996), and 244 non-English country representation was at most 43.8% (corresponding authors in 2020). The first 245 authors exhibited a greater representation of LMIC and non-English countries than the last 246 authors. Following initial growth, the rate plateaued from about 2009 for non-English 247 representation, and exhibited a decrease after 2012 for LMIC status. The results of the logistic 248 regression modelling showed that the effect of year on the proportion of articles in each diversity 249 index varied between 0.997 and 1.029 with *P*-values < 0.001 except for Spanish-speaking and the 250 last author from LMICs models (Appendix 7).



B non-English-speaking vs. English-speaking



Figure 2. Region diversity in Cochrane Reviews authorship. (A) low-and-middle-income countries (LMICs) vs. non-LMICs. (B) non-English-speaking vs. English-speaking. (C) non-Spanish-speaking vs. Spanish-speaking. Please note that the y-axis for C is magnified to 0%-256 25%.

257

258 Gender diversity

Over time, female first authorship increased from about a quarter in 1997 (27.7%) to more than half in 2023 (50.8%). Percentages of female corresponding and last authors likewise increased; however, growth was less pronounced for the last authors (39.4% in 2023; Figure 3). Logistic regression modelling showed that the coefficient for the year ranged between 1.015 and 1.030 with *P*-values <0.001 (Appendix 7).

264



265

266 Figure 3. Gender diversity in Cochrane Reviews authorship.

268 **Diversity among Review Groups**

269 Across author categories, most CRGs had 10-25% reviews with authors from LMICs and 25-270 50% of reviews with authors from non-English speaking countries, across author categories 271 (Table 2). Seven CRGs had less than 10% of reviews with first authors from LMICs, and seven 272 CRGs had 10-20% of first authors from non-English countries. The Sexually Transmitted 273 Infections Review Group had the highest proportion of reviews with authors from LMICs 274 (first=68.1%, corresponding=66.0%, and last authors=57.4%). This was the only CRG with 275 representation above 50% of LMICs for all three author categories. HIV/AIDS and Infectious 276 Diseases had the next highest LMIC representation, with 50.6% and 41.1% of first authors from 277 these countries. Childhood Cancer (n=118 reviews; now closed) had the highest proportion of 278 reviews with authors from non-English-speaking countries (87% of the three author categories 279 combined). Lower geographical diversity was observed in the Consumers and Communication 280 group, with 1.6% and 13.3% of reviews with first authors from LMICs and non-English 281 countries, respectively.

Most CRGs had more than 50% of reviews with female first and corresponding authors, however, a majority of CRGs had 20-50% of reviews with female last authors, suggesting a 'ceiling' for this author category. Fertility Regulation had the highest percentage of female first authors (72.1%), followed by Consumers and Communication (69.1%), and Skin (66.6%). Lower representation of female first authors was observed for reviews from the Urology, Hepato-Biliary, and Colorectal Groups (less than 35%). Appendix 8 shows bar plots of geographical and gender diversity for each CRG and Appendix 9 presents percentages.

Table 2. Number of CRGs with indicated proportions of reviews with first, corresponding, and last authors, that are from LMICs, non-English speaking countries and Female. Proportion categories were selected to best represent the data.

| Proportion of reviews | First authors | Corresponding authors | Last authors |
|-----------------------|---------------|-----------------------|--------------|
| LMICs | | | |
| [0–10%) | 7 | 6 | 9 |
| [10-25%) | 33 | 33 | 35 |

| [25–50%) | 11 | 13 | 8 |
|--------------------------------|----|----|----|
| [50–100%] | 2 | 1 | 1 |
| Non-English-speaking countries | | | |
| [0–10%) | 0 | 0 | 0 |
| [10–25%) | 7 | 7 | 7 |
| [25–50%) | 30 | 30 | 33 |
| [50–100%] | 16 | 16 | 13 |
| Female (by first name) | | | |
| [0–10%) | 0 | 0 | 0 |
| [10–25%) | 0 | 0 | 8 |
| [25–50%) | 20 | 26 | 38 |
| [50–100%] | 33 | 27 | 7 |

292 LMICs: Low-and-middle-income countries

293

The results of Fisher's exact test showed a *P*-value<0.001 for all the comparisons between review groups in terms of geographical and gender diversity. The random intercept generalized linear mixed-effects logistic models showed higher random effects variance for the effect of CRGs for Spanish-speaking models (about 1) and lower for female models (less than 0.2). Full details are available in Appendix 2 and 10.

299

300 Comparison with non-Cochrane reviews

301 We retrieved 224,484 non-Cochrane systematic reviews, representing the period 1987 to 2024.

302 Lack of information in first author affiliations precluded assigning country and language status

for 41,266 (18.4%), and income region for 43,315 (19.3%) of reviews. Gender could not be

assigned for 39,619 (17.6%) first authors.

In 1996, of 60 non-Cochrane reviews, none included first authors that were female, from LMICs, or from Spanish-speaking countries; however, 11 (18.3%) reviews had first authors from non-

English-speaking countries. In 2023, of 25,629 reviews, over half had first authors from non-English-speaking countries (n=14,589, 56.9%), 50.8% (n=13,014) had first authors from LMICs and 42.3% (n=10,841) had female first authors (Figure 4).

310 Trends over time exhibit notable differences compared to those observed with Cochrane reviews. 311 One, the proportion of first authors in non-Cochrane reviews from LMICs is above 15% from 312 1996 to 2012, then exhibits a sharp increase to 41.0% in 2014, followed by a steady increase to 313 50.8% in 2023 (Figure 4); all in all, proportions over the period are higher than for Cochrane 314 reviews, which are exhibit a relatively plateaued rate of growth (Figure 2). Two, the proportion 315 of first authors of non-Cochrane reviews from non-English speaking countries starts at about 316 20% in 1996 and increases steadily to reach approximately 60% in 2023; the rate of growth for 317 non-English speaking authors, regardless of author type, is lower in Cochrane reviews, where 318 proportion does not reach 50% (Figure 2). Three, first authors from Spanish-speaking countries 319 comprise less than 3% until the 2020s in which we see an increase to above 3% with 3.9% at its 320 highest in 2021. Four, a sizable representation of female authorship in non-Cochrane reviews 321 appears in 2002, starting at 28.0% (Figure 4), and continues to grow to 42.3% in 2023. In 322 contrast, female representation in Cochrane reviews has been stable across author types since 323 about the year 2000, and for first authors, it peaks in 2023 at 55.6% (Figure 2).







327

The results of the Granger Causality Test showed *P*-values of 0.062, 0.701, 0.483, and 0.499 when comparing LMIC, non-English speaking, Spanish-speaking, and female first authorship trends between Cochrane and non-Cochrane reviews. This means the non-Cochrane and Cochrane trends may not be predictive of each other. The Pearson's product-moment correlations were 0.265 (*P*=0.450), 0.823 (*P*<0.001), 0.634 (*P*<0.001), and 0.829 (*P*<0.001), respectively.

334 Validation

The validation sample contained 1134 reviews. There were no discrepancies between the automatic algorithm and manual checking (Appendix 4).

338

339

340 **Discussion**

341 This work represents a comprehensive evaluation of geographic and gender diversity among 342 Cochrane reviews since the first Cochrane review was published in 1995. We showed that the 343 first author representation from LMICs peaked at 26.7% in 1996 and at 43.8% in 2020 for non-344 English speaking countries. Both categories exhibited growing rates through to approximately 345 2010, followed by plateau periods. From 2015, representation from LMICs exhibited a decline, 346 decreasing to 16.2% in 2023. Overall, authors were predominantly from high-income and 347 English-speaking countries, approximately 80% and 60%, respectively, and of English-speaking 348 countries, predominantly from the UK (approximately one-third of all authors). Despite a very 349 active community of researchers from Spanish-speaking countries in Cochrane, evidenced by a 350 sizable proportion of Geographic Groups and a dedicated conglomerate (Cochrane 351 Iberoamerica), author representation from Spanish-speaking countries was low. Non-Cochrane 352 reviews were more diverse in having a higher proportion of first authors from LMICs (50.8% vs. 353 18.4% in 2023) and non-English-speaking countries (56.9% vs. 42.8% in 2023).

These results echo findings from previous work in specific medical fields, showing poor representation of Cochrane review authors from LMICs in the disciplines of hematology (9), gastroenterology (11), and cardiology (13). Additionally, just 12% of Cochrane's 111,000 members were based in an LMIC in 2022 (6). Low representation of authors from LMICs may be, in part, due to the limited investment in research funding, academic institutions, and infrastructure in these countries, and in contrast, a greater relative investment in high-income countries (30).

These findings may suggest that the focus on international collaboration and standardized methodologies in Cochrane Reviews might unintentionally favour authors from high-income, English-speaking regions. The long time it takes to publish reviews could also be another barrier. New mechanisms to engage qualified researchers from a more diverse range of geographical locations to participate in Cochrane reviews might be needed. These findings may also reflect

366 limited processes in Cochrane to ensure that individuals from LMICs are trained in Cochrane 367 review production, and are more actively included in author teams. For example, while there are 368 initiatives such as free access for LMIC authors to a suite of state-of-the-art online training 369 modules, perhaps greater promotion to, and engagement with, LMIC members may help to 370 increase author representation. Similarly, initiatives such as Cochrane Exchange (formerly Task 371 Exchange), which are used to post review tasks to a wide audience, could potentially be used to 372 invite authors from LMIC countries to participate in author teams more systematically, 373 especially on topics where a global perspective.

Despite the low prevalence of LMIC-led Cochrane reviews, 22,681 Cochrane reviews included authors from 107 countries across author types, including at least 59 LMIC countries (55.1%), exhibiting significant diversity and demonstrating that academic research is indeed a global endeavour that involves contributions from scholars all across the world.

378 Since 1996, there has been a steady increase in female authorship in Cochrane reviews across the 379 three author categories (first, corresponding, and last). Female first authors increased from 15.0% 380 in 1996 to 55.6% in 2023. This is in line with research by Bhat (13) who found that the 381 representation of females as first authors of Cochrane cardiology reviews had increased over 382 time. In contrast to non-Cochrane reviews, the rate of growth for female first authors in 383 Cochrane reviews is higher. There are a number of reasons that may contribute to the observed 384 changes in gender representation. It is plausible that initiatives aimed at fostering gender equality 385 in academia and research, an increasing appreciation of the importance of diversity and equity, 386 and broader societal shifts toward recognizing and addressing gender disparities in various 387 professional fields have played a role in encouraging and supporting female researchers to 388 assume authorship roles. The greater proportions in 2023, and higher growth rate over time, for 389 female first authors of Cochrane reviews relative to non-Cochrane reviews suggest dedicated 390 initiatives on this front within the organisation. However, the rate of growth for female last 391 authors in Cochrane reviews is evidently lower, representing about a third of last authors in 392 2023, compared to approximately half of first authors the same year. Further, while 33 of 52 393 CRGs had more than 50% of reviews authored by female first authors, a majority of CRGs had 394 25-50% female last authors (n=38), similarly exhibiting a ceiling effect for this author category. 395 This is notable given that last authors typically represent senior positions on a review team, and

may suggest that additional factors or barriers may influence the advancement of women intohigher-ranking authorship roles within Cochrane.

398 Our findings also suggested varying diversity between Cochrane Review Groups. In the future, it 399 would be interesting to explore how Cochrane Review Groups achieve diversity in authorship 400 and encourage shared learning between groups, particularly within the changing landscape of 401 Cochrane review production. The number of Cochrane Review Groups has reduced since 2023 402 when the National Institute for Health and Care Research ceased funding for the Cochrane 403 Review Groups that were based in the United Kingdom (31). At the same time, seven "Cochrane 404 Thematic Groups" were created, each focusing on an aspect of healthcare (32). Cochrane also 405 introduced "Evidence Synthesis Units" which focus on developing locally and regionally 406 relevant evidence and responding to diverse stakeholder needs (33). It is important that the 407 remaining Cochrane Review Groups, and the new thematic groups, prioritize diversity and 408 inclusion in review production.

409 **Implications**

410 The findings of this study have potential implications for Cochrane review production. It is clear 411 that Cochrane needs to do more to improve the inclusion of individuals from LMICs. Supporting 412 individuals from LMICs as authors of Cochrane reviews will encourage varying perspectives, interests, and priorities. This is likely to lead to a wider coverage of health topics, a stronger 413 414 focus on health equity, and attention to conditions with a high global burden of disease. In turn, 415 this will help to ensure that harder-to-reach groups within the population benefit from Cochrane 416 evidence and that intervention-generated inequalities are avoided (34). Also, it is shown that 417 higher authorship of underrepresented groups in Cochrane reviews is associated with greater 418 considerations of equity-related analyses in the reviews (e.g., females (35)). The Cochrane 419 Health Equity Thematic Group is well positioned to help in this effort, as the Group aims to 420 promote health equity within Cochrane, by supporting CRGs and author teams to consider health 421 equity in their work, and by developing and evaluating methods to analyze health equity in 422 systematic reviews and the evidence base (36). Working together with other organizations 423 globally will also be crucial to improving the inclusion of people from LMICs. An example of 424 such collaboration is the Global Evidence Synthesis Initiative (37).

425 The finding that there is a gender disparity in leadership roles in Cochrane reviews suggests that 426 Cochrane would benefit from exploring ways to support female authors into senior author roles. 427 Future research should explore potential challenges or biases that may hinder the progression of 428 female researchers. Identifying and addressing these barriers, which could encompass 429 institutional practices, and biases in funding and mentorship opportunities (38), is crucial for 430 achieving a more equitable distribution of authorship responsibilities. In 2022, the U.S. National 431 Institutes of Health developed new initiatives to promote gender equity. For example, they offer 432 additional financial support to assist researchers in maintaining their work during childbirth, 433 adoption, and primary caregiving duties. Additionally, they are acknowledging institutions that 434 effectively tackle gender diversity and equity concerns, thereby promoting the adoption of 435 proven, replicable strategies for enhancing faculty diversity (39).

Regarding geographical diversity, further research investigating citation metrics, collaboration
patterns, and the significance of the research may provide a more comprehensive understanding
of the impact of Cochrane reviews, and of the make-up of the entirety of author teams.

439 Strengths and limitations

440 Strengths of this study include that it followed a pre-registered protocol and used a fully 441 reproducible methodology to systematically extract and analyze data from Cochrane reviews. 442 Data was extracted from Cochrane reviews using an automated technique, allowing for the 443 collection of a large amount of data. Additionally, the study was conducted by a diverse and 444 international team of researchers with varying backgrounds in healthcare.

445 Limitations include that we were unable to identify the country for 318 affiliations due to 446 insufficient information on the website. This could be an area for improvement in data collection 447 or reporting standards. Additionally, as the variable gender was inputted with the use of the 448 World Gender Name Dictionary (WGND) 2, there is room for error in classification. Even 449 though this dictionary includes an extensive list of names from many languages, our variable 450 gender is a probabilistic proxy. However, we believe that even if we had the gender ground truth, 451 our results would not change significantly given two reasons: (1) diversity increases in other 452 variables, thus is likely to have an increase also in gender; and (2) the WGND 2 usability, thus is 453 the closest that we have to ground truth and it has been used in research elsewhere, providing a

powerful tool with no systematic biases. Additionally, this tool has been used in other studies
(40–45). The use of an automated process to collect data also has potential limitations. For
example, data cleaning is a complex procedure and prone to errors if not tested adequately.
However, this was a pragmatic approach and allowed for the collection of a large amount of data
that would have otherwise been impossible with the available resources.

459 **Conclusions**

460 Our analysis of Cochrane Reviews revealed progress in gender diversity, with a significant 461 increase in female first authors. However, geographic diversity remains limited, with an 462 overrepresentation of authors from high-income, English-speaking countries. Notably, diversity 463 varied across Review Groups, with Sexually Transmitted Infections exhibiting the highest 464 representation from non-English speaking and low/middle-income countries. While non-465 Cochrane reviews showed a similar trend of increasing diversity, no causal relationship between 466 Cochrane and non-Cochrane review trends was observed. These findings suggest that while 467 progress has been made in gender representation, further efforts are needed to enhance 468 geographic diversity within Cochrane Reviews. Strategies such as fostering international 469 collaborations and exploring alternative authorship models could be implemented to achieve this 470 goal.

471 Author contributions

Conceptualization: ASM, EV, SCO, ABP; Data curation: ASM; Formal analysis: ASM, JS, ET;
Investigation: ASM, EV, ABP, EN, AS, LEM; Methodology: ASM, JS, EV, SK, SCO; Project
administration: ASM; Resources: ASM; Software: ASM; Supervision: ASM; Validation: ASM,
SK; Visualization: ASM, JS, LM; Roles/Writing - original draft: ASM, JS, EV, ET, ABP, SK,
EN, AS, LEM; ACBJ, SCO and Writing - review & editing: ASM, JS, EV, ET, ABP, SK, EN,
AS, LEM; ACBJ, SCO, VAW, LM, PT.

478 **References**

- 1. Cochrane. About us [Internet]. [cited 2024 Feb 27]. Available from:
- 480 https://www.cochrane.org/about-us

- 481
 481
 482
 482
 482
 483
 484
 484
 484
 485
 485
 486
 486
 486
 487
 487
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
- 483
 483
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
- 485
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
- 487 5. Cochrane. Cochrane Membership [Internet]. [cited 2024 Mar 23]. Available from: 488 https://www.cochrane.org/icin.cochrane/membership
- 488 https://www.cochrane.org/join-cochrane/membership
- 6. Cochrane. How could Cochrane be even more inclusive? Feedback from over 1300 people
 [Internet]. Cochrane; 2022 [cited 2024 Feb 27]. Available from:
 https://www.cochrane.org/sites/default/files/public/uploads/pdf/cochrane-listen-and-learndiversity.pdf
- 493
 7. Cochrane. Current Cochrane Group Priority Setting Projects [Internet]. [cited 2024 Feb 27].
 494
 495
 495
 496
 497
 498
 498
 498
 499
 499
 499
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 491
 491
 492
 493
 494
 495
 494
 495
 495
 495
 495
 495
 496
 496
 497
 497
 498
 498
 498
 498
 498
 498
 499
 499
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
- 496 8. Tomlinson E, Pardo Pardo J, Sivesind T, Szeto MD, Laughter M, Foxlee R, et al. Prioritising
 497 Cochrane reviews to be updated with health equity focus. Int J Equity Health. 2023 May
 498 5;22(1):81.
- 499 9. Biswas J, Dhali A, Rathna RB, D'Souza C. Authorship diversity in hematology□related
 500 Cochrane systematic reviews: Inequities in global representation. Res Pract Thromb
 501 Haemost. 2022 Aug;6(6):e12778.
- 502 10. Qureshi R, Han G, Fapohunda K, Abariga S, Wilson R, Li T. Authorship diversity among
 503 systematic reviews in eyes and vision. Syst Rev. 2020 Dec;9(1):192.
- 504 11. Dhali A, D'Souza C, Rathna RB, Biswas J, Dhali GK. Authorship diversity in
 505 Gastroenterology-related Cochrane systematic reviews: Inequities in global representation.
 506 Front Med. 2022 Sep 2;9:982664.
- 507 12. Evans J, Mwangi N, Burn H, Ramke J. Equity was rarely considered in Cochrane Eyes and
 508 Vision systematic reviews and primary studies on cataract. J Clin Epidemiol. 2020
 509 Sep;125:57–63.
- 510 13. Bhat V, Ozair A, Bellur S, Subhash NR, Kumar A, Majmundar M, et al. Inequities in
 511 Country- and Gender-Based Authorship Representation in Cardiology-Related Cochrane
 512 Reviews. JACC Adv. 2022 Dec;1(5):100140.
- 14. Rathna RB, Biswas J, D'Souza C, Joseph JM, Kipkorir V, Dhali A. Authorship diversity in
 general surgery-related Cochrane systematic reviews: a bibliometric study. Br J Surg. 2023
 Jul 17;110(8):989–90.
- 516
 15. Tomlinson E, Petkovic J, Welch V, Tugwell P. It's time to increase the global relevance of
 517
 Cochrane Reviews by applying an 'equity lens.' Cochrane Editorial Unit, editor. Cochrane
 518
 518 Database Syst Rev [Internet]. 2021 Oct 28 [cited 2023 Dec 4];2021(10). Available from:
 519
 http://doi.wiley.com/10.1002/14651858.ED000155
- 520 16. O'Neill J, Tabish H, Welch V, Petticrew M, Pottie K, Clarke M, et al. Applying an equity
 521 lens to interventions: using PROGRESS ensures consideration of socially stratifying factors
 522 to illuminate inequities in health. J Clin Epidemiol. 2014 Jan;67(1):56–64.
- 523 17. Mbuagbaw L, Schoonees A, Oliver J, Arikpo D, Durão S, Effa E, et al. Publication practices
 524 of sub-Saharan African Cochrane authors: a bibliometric study. BMJ Open. 2021
 525 Sep;11(9):e051839.
- 526 18. Martínez GL, de Juano-i-Ribes HS, Yin D, Le Feuvre B, Hamdan-Livramento I, Saito K, et

- al. Expanding the World Gender-Name Dictionary: WGND 2.0. World Intellectual Property
 Organization-Economics and Statistics Division; 2021.
- 529 19. Ameratunga D, Yazdani A, Kroon B. Antibiotics prior to or at the time of embryo transfer in
 530 ART. Cochrane Gynaecology and Fertility Group, editor. Cochrane Database Syst Rev
 531 [Internet]. 2023 Nov 23 [cited 2023 Dec 2];2023(11). Available from:
- 532 http://doi.wiley.com/10.1002/14651858.CD008995.pub3
- 20. Cundy O, Lange CA, Bunce C, Bainbridge JW, Solebo AL. Face-down positioning or
 posturing after macular hole surgery. Cochrane Eyes and Vision Group, editor. Cochrane
 Database Syst Rev [Internet]. 2023 Nov 21 [cited 2023 Dec 2];2023(11). Available from:
 http://doi.wiley.com/10.1002/14651858.CD008228.pub3
- 537 21. Heneghan M, Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or
 538 without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most
 539 commonly F508del). Cochrane Cystic Fibrosis and Genetic Disorders Group, editor.
 540 Cochrane Database Syst Rev [Internet]. 2023 Nov 20 [cited 2023 Dec 2];2023(11). Available
 541 from: http://doi.wiley.com/10.1002/14651858.CD010966.pub4
- 22. Roberts L, Lin L, Alsweiler J, Edwards T, Liu G, Harding JE. Oral dextrose gel to prevent
 hypoglycaemia in at-risk neonates. Cochrane Neonatal Group, editor. Cochrane Database
 Syst Rev [Internet]. 2023 Nov 28 [cited 2023 Dec 2];2023(11). Available from:
- 545 http://doi.wiley.com/10.1002/14651858.CD012152.pub4
- 546 23. Tunnicliffe DJ, Palmer SC, Cashmore BA, Saglimbene VM, Krishnasamy R, Lambert K, et
 547 al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not
 548 requiring dialysis. Cochrane Kidney and Transplant Group, editor. Cochrane Database Syst
 549 Rev [Internet]. 2023 Nov 29 [cited 2023 Dec 2];2023(11). Available from:
 550 http://doi.wiley.com/10.1002/14651858.CD007784.pub3
- 551 24. Sayers E. E-utilities Quick Start. In: Entrez Programming Utilities Help [Internet]. Bethesda
 552 (MD): National Center for Biotechnology Information (US); 2008 [cited 2024 Feb 27].
 553 Available from: https://www.ncbi.nlm.nih.gov/books/NBK25500/
- S54 25. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna,
 S55 Austria: R Foundation for Statistical Computing; 2023. Available from: https://www.R S56 project.org/
- 557 26. Wickham H. rvest: Easily Harvest (Scrape) Web Pages [Internet]. 2022. Available from:
 558 https://CRAN.R-project.org/package=rvest
- 559 27. Wickham H. ggplot2: Elegant Graphics for Data Analysis. 2016; Available from:
 560 https://ggplot2.tidyverse.org
- 561 28. Granger CWJ. Investigating Causal Relations by Econometric Models and Cross-spectral
 562 Methods. Econometrica. 1969 Aug;37(3):424.
- 563 29. Hiemstra C, Jones JD. Testing for Linear and Nonlinear Granger Causality in the Stock
 564 Price Volume Relation. J Finance. 1994 Dec;49(5):1639–64.
- 30. Franzen SRP, Chandler C, Lang T. Health research capacity development in low and middle
 income countries: reality or rhetoric? A systematic meta-narrative review of the qualitative
 literature. BMJ Open. 2017 Jan 27;7(1):e012332.
- 568 31. Pearson H. Medical-evidence giant Cochrane battles funding cuts and closures. Nature. 2023
 569 Sep 7;621(7977):13–4.
- 570 32. Cochrane. Major milestones and new beginnings: Cochrane announces first round of new
 571 Thematic Groups [Internet]. [cited 2024 Mar 23]. Available from:
- 572 https://community.cochrane.org/news/major-milestones-and-new-beginnings-cochrane-

- 573 announces-first-round-new-thematic-groups
- 574 33. Cochrane. About Cochrane's new production model [Internet]. [cited 2024 Mar 23].
- 575 Available from: https://community.cochrane.org/organizational-info/plans/future-evidence-576 synthesis-cochrane/about-cochranes-new-production-model
- 34. Welch VA, Petkovic J, Jull J, Hartling L, Klassen T, Kristjansson E, et al. Equity and
 specific populations. In: Cochrane Handbook for Systematic Reviews of Interventions.
 Wiley Online Library; 2019. p. 433–49.
- 35. Antequera A, Cuadrado-Conde MA, Roy-Vallejo E, Montoya-Martínez M, León-García M,
 Madrid-Pascual O, et al. Lack of sex-related analysis and reporting in Cochrane Reviews: a
 cross-sectional study. Syst Rev. 2022 Dec 26;11(1):281.
- 36. Parker R, Petkovic J, Pardo Pardo J, Darzi A, Dewidar O, Khabsa J, et al. The equity group:
 Supporting Cochrane's social responsibility of improving health equity. Cochrane Evid
 Synth Methods. 2023;1(3):e12012.
- 586 37. Cochrane. Beirut the new home of Global Evidence Synthesis Initiative [Internet]. [cited
 587 2024 Mar 23]. Available from: https://www.cochrane.org/news/beirut-new-home-global588 evidence-synthesis-initiative
- 38. Association of American Medical Colleges. The State of Women in Academic Medicine
 2018-2019: Exploring Pathways to Equity [Internet]. Association of American Medical
 Colleges; 2020. Available from: https://store.aamc.org/the-state-of-women-in-academicmedicine-2018-2019-exploring-pathways-to-equity.html
- 39. Ten Hagen KG, Wolinetz C, Clayton JA, Bernard MA. Community voices: NIH working
 toward inclusive excellence by promoting and supporting women in science. Nat Commun.
 2022 Mar 25;13(1):1682.
- 40. Bhagat V. Data and Techniques Used for Analysis of Women Authorship in STEMM: A
 Review. Fem Res. 2019 Oct 2;2(2):76–87.
- 598 41. Forkin KT, Render CM, Staffa SJ, Goobie SM. Trends in Gender of Authors of Patient
 599 Blood Management Publications. Anesth Analg [Internet]. 2023 Dec 28 [cited 2024 Mar 23];
 600 Available from: https://journals.lww.com/10.1213/ANE.00000000006749
- 42. Chien CV, Ouellette LL. Improving equity in patent inventorship. Science. 2023 Dec
 8;382(6675):1128–9.
- 43. Hattke F, Vogel R. Theories and theorizing in public administration: A systematic review.
 Public Adm Rev. 2023 Nov;83(6):1542–63.
- 44. Lax-Martinez G, Raffo JD, Saito K. Identifying the gender of PCT inventors. SSRN Electron
 J [Internet]. 2023 [cited 2024 Mar 23]; Available from:
- 607 https://www.ssrn.com/abstract=4434107
- 45. Keenan P, Heavin C. DSS research: a bibliometric analysis by gender. J Decis Syst. 2022
 Dec 15;31(sup1):107–16.







B non-English-speaking vs. English-speaking



C Spanish-speaking vs. non-Spanish-speaking









